Correction. "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748

We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms

Enfrentando os limites do crescimento

Desde os anos 1960, os ambientalistas e cientistas vêm alertando sobre o perigo do colapso ambiental. Os relatórios das agência da onu e de instituições como o World Watch Institute mostram de forma contundente a urgência de uma mudança radical para evitar esse colapso. A novidade è que um número crescente de economistas, até então defensores do crescimento como panaceia para resol ver todos os problemas, agora fala dos limites do crescimento e da necessidade de “mudar de economia”, tanto para evitar o colapso como para alcançar a justiça social. O mais recente relatório da ocde (Previsões ambientais para 2050: as consequências da inação”, de 2012) faz um alerta dramático nesse sentido. Entretanto, tanto a postura dos responsáveis políticos quanto as sohições que vêm sendo propostas (do desenvolvimento sustentável à economia verde) estão muito aquém do esperado. Não atacam a raiz do problema: o atual mo delo de produção e consumo já é insustentável, e o será ainda mais quando for generalizado. Esta evidência leva a uma conclusão incontornãvel: a necessidade de justiça social e ambiental nas relações entre os países e no interior de cada país, única forma de tornar aceitáveis (ética, social e politicamente) as mudanças indispensáveis. Para sobreviver, o nosso sistema econômico précisa oferecer cada vez mais objetos com obsolescência cada vez mais precoce, consumindo assim cada vez mais recursos e produzindo mais lixo. A eficiência produtiva crescente (fazer mais com menos matéria e menos energia) é uma realidade, mas essa eficiêticia tem poucos resultados em face do aumento do consumo global. Portanto, é urgente passarmos da competição para a colaboração; sem isto, os conflitos em torno de recursos cada vez mais raros e mais caros serão devastadores. É urgente passarmos de um mundo que estimula uma busca frustrante e sem fim por mais consumo para uma sociedade de consumo baixo, mas de qualidade, que se oriente para a felicidade individual e coletiva. Normalmente tais mudanças requereriam séculos, mas não dispomos desse tempo. O futuro é hoje! Os textos reunidos neste livro apresentam análises sobre várias dimensões desta problemática, tentando entender as lógicas e interesses em jogo, as causas da inação atual e os possíveis caminhos para sair do impasse

Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC

The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most common type of PCL, none exist for the other PCLs. In addition, staging of the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous LymphomaConsortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints, and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Acknowledgements: The authors thank the leadership and staff of the International Agency for Research on Cancer, especially Ms. Asiedua Asante, for her tireless efforts, and also Jasmine Singh and Kim Vu for their expert assistance in graphic presentation of the river plot figures.We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms